Publications

2021

• Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection

  • Ococks E, Sharma S, Ng AW, Aleshin A, Fitzgerald RC, Smyth E; OCCAMS Consortium. Gastroenterology. 2021 Jul 17:S0016-5085(21)03245-5. doi: 10.1053/j.gastro.2021.07.011. Epub ahead of print. PMID: 34284036.

• Longitudinal sampling of 97 Oesophageal adenocarcinoma using liquid biopsy sampling

  • Ococks E, Frankell AM, Masque Soler N, Grehan N, Northrop A, Coles H, Redmond AM, Devonshire G, Weaver JMJ, Hughes C, Lehovsky K, Blasko A, Nutzinger B; OCCAMS Consortium, Fitzgerald RC, Smyth E. Ann Oncol. 2021 Apr;32(4):522-532.

2020

• Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus.

  • Knight WRC, McEwen R, Byrne BE, Habib W, Bott R, Zylstra J, Mahadeva U, Gossage JA; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Eur J Surg Oncol. 2020 Jul:S0748-7983(20)30576-X. doi: 10.1016/j.ejso.2020.07.003.

• Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to Oesophageal Adenocarcinoma

  • Rogerson C., Ang Y., Sharrocks A.D. at al. on behalf of the OCCAMS Consortium has been published in eLife, 2020 Sep 3; 9:e57189. PMID: 32880368.

• Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data

  • Jammula S, Katz-Summercorn AC, Li X, Linossi C, Smyth E, Killcoyne S, Biasci D, Subash VV, Abbas S, Blasko A, Devonshire G, Grantham A, Wronowski F, O'Donovan M, Grehan N, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) consortium, Fitzgerald RC. Gastroenterology. 2020 May;158(6):1682-1697.

• Machine learning to predict early recurrence after oesophageal cancer surgery

  • Rahman SA, Walker RC, Lloyd MA, Grace BL, van Boxel GI, Kingma BF, Ruurda JP, van Hillegersberg R, Harris S, Parsons S, Mercer S, Griffiths EA, O'Neill JR, Turkington R, Fitzgerald RC, Underwood TJ; OCCAMS Consortium.Br J Surg. 2020 Jul;107(8):1042-1052.

2019

• Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma

  • Mourikis TP, Benedetti L, Foxall E, Temelkovski D, Nulsen J, Perner J, Cereda M, Lagergren J, Howell M, Yau C, Fitzgerald RC, Scaffidi P; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Ciccarelli

• Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

  • Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P; OCCAMS Consortium, Fitzgerald RC. Int J Cancer. 2019 Dec 15;145(12):3389-3401. doi: 10.1002/ijc.32384. Epub 2019 May 17FD. Nat Commun. 2019 Jul 15;10(1):3101. doi: 10.1038/s41467-019-10898-3.

• Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

  • Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9

• The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.

  • Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, Grehan N, Mok J, O'Donovan M, MacRae S, Eldridge MD, Tavaré S; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Fitzgerald RC. Nat Genet. 2019 Mar;51(3):506-516. doi: 10.1038/s41588-018-0331-5. Epub 2019 Feb 4.

2018

• Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

  • Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium. Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27

• Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

  • Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Oncotarget. 2018 Apr 6;9(26):18518-18528. doi: 10.18632/oncotarget.24906. eCollection 2018 Apr 6

2017

• Corrigendum: A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

  • Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Genome Res. 2017 Oct;27(10):1782. doi: 10.1101/gr.229153.117

• Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

  • Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Br J Surg. 2017 Dec;104(13):1816-1828. doi: 10.1002/bjs.10627. Epub 2017 Sep 25

• Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma.

  • Britton E, Rogerson C, Mehta S, Li Y, Li X; OCCAMS consortium, Fitzgerald RC, Ang YS, Sharrocks AD. PLoS Genet. 2017 Aug 31;13(8):e1006879. doi: 10.1371/journal.pgen.1006879. eCollection 2017 Aug

• Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis.

  • Fels Elliott DR, Perner J, Li X, Symmons MF, Verstak B, Eldridge M, Bower L, O'Donovan M, Gay NJ; OCCAMS Consortium, Fitzgerald RC. PLoS Genet. 2017 May 22;13(5):e1006808. doi: 10.1371/journal.pgen.1006808. eCollection 2017

• Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

  • Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Nat Genet. 2017 Jan 31;49(2):317. doi: 10.1038/ng0217-317a.

2016

• Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

  • Garcia E, Hayden A, Birts C, Britton E, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417.

• Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

  • Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Nat Genet. 2016 Oct;48(10):1131-41. doi: 10.1038/ng.3659. Epub 2016 Sep 5

2014

• Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

  • Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CJ, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O'Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PAW, Rosenfeld N, Tavaré S, Fitzgerald RC; OCCAMS consortium. Nat Genet. 2014 Aug;46(8):837-843. doi: 10.1038/ng.3013. Epub 2014 Jun 22

2010

• A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

  • Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Gastroenterology. 2010 Dec;139(6):1995-2004.e15. doi: 10.1053/j.gastro.2010.05.080. Epub 2010 Jun 2